Concept graphic for future treatment of mast cell disease. Typical shadow figure with typical icons of science (microscope, vials, petri dish, test tubes)

Welcome to the latest “Allergy, Asthma & Immunology Innovations” episode. This episode is the latest in our series about mast cell diseases. It focuses on mastocytosis, the role of bone marrow in diagnosis, and KIT Inhibitors in clinical trials for treating systemic mastocytosis.

You can listen to or download the podcast on ItchPodcast.com for listening anytime, anywhere. The podcast can also be downloaded at:

The podcast series is sponsored by Blueprint Medicines.

The role of bone marrow in mastocytosis

Podcast hosts Kortney Kwong Hing and Payel Gupta, MD are joined by Douglas Tremblay, MD, a hematologist-oncologist at the Icahn School of Medicine at Mount Sinai and principal investigator on numerous initiatives, including clinical trials for KIT inhibitor bezulastinib.

Dr. Tremblay explains the importance of a bone marrow biopsy in diagnosing systemic mastocytosis. He describes the function of bone marrow, what a patient can expect when having a bone marrow biopsy, and what doctors are looking for when evaluating patients for mastocytosis.

Latest research in mastocytosis treatment

Dr. Tremblay discusses the bone marrow’s function and the KIT mutation’s role in mast cell disease. Then he delves into KIT inhibitors, explaining their function, the risks and benefits for patients, and how he performs clinical trials for mastocytosis.

Learn more about the role of bone marrow in systemic mastocytosis and the exciting new developments with KIT inhibitors.

Podcast Timestamps

01:49 – Hematologist’s role in diagnosing and treating mast cell disease

04:51 – Bone marrow biopsy: what is it, and why is it needed for mastocytosis

08:14 – KIT mutation

09:58 – KIT mutation testing (digital droplet PCR)

12:23 – Current research for treating mast cell disease

13:58 – KIT inhibitors: Avapritinib, Bezuclastinib, Elanestinib

17:36 – Indolent mastocytosis versus advanced mastocytosis

18:38 – How the KIT inhibitors work

21:31 – What does ‘NIB’ mean in the medication name?

22:53 – Are KIT inhibitors a cure for mast cell disease?

25:33 – Do KIT inhibitors weaken the immune system?

27:33 – Timeline for the new KIT inhibitors’ FDA approval

 

Additional Resources